Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Omeros Corporation - Common Stock (NQ:OMER)

12.59 +0.03 (+0.20%)
Streaming Delayed Price Updated: 11:10 AM EDT, Aug 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Omeros Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
CMS Grants New Technology Add-On Payment (NTAP) Status to YARTEMLEA®
From Omeros Corporation
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - OMER
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
From Pomerantz LLP
Via GlobeNewswire
Omeros Corp (NASDAQ:OMER) Swings to Profit on YARTEMLEA Launch, Topping EPS Forecasts ↗
Via Chartmill
Omeros Corp (NASDAQ:OMER) Reports Q4 2025 Earnings Boosted by Major Asset Sale, Launches First Commercial Product ↗
Via Chartmill
News headline image
Heartflow vs. Omeros: Which Healthcare Innovator Stock Is a Better Buy in 2026? ↗
Heartflow boasts rapid AI-driven growth but faces reimbursement headwinds, while Omeros bets everything on its first commercial launch. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
OMER Investors Have Opportunity to Join Omeros Corporation Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
From Pomerantz LLP
Via GlobeNewswire
News headline image
OMER Investors Have Opportunity to Join Omeros Corporation Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Which stocks are moving on Friday? ↗
Via Chartmill
Traders are paying attention to the gapping stocks in Friday's session. ↗
Via Chartmill
Top movers in Friday's pre-market session ↗
Via Chartmill
News headline image
Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMA
From Omeros Corporation
Via Business Wire
News headline image
NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026? ↗
Both companies target serious health challenges, but their financials and risk profiles reveal sharply different paths for growth-focused investors. 
Via The Motley Fool
News headline image
Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026? ↗
Intellia's CRISPR pipeline and Omeros's newly approved therapy each bring unique risk and reward profiles, see how their financials and partnerships compare. 
Via The Motley Fool
News headline image
Omeros Announces Webcast Details for Annual Meeting of Shareholders
From Omeros Corporation
Via Business Wire
News headline image
Omeros (OMER) Q4 2025 Earnings Transcript ↗
Omeros (OMER) Q4 2025 Earnings Transcript 
Via The Motley Fool
Topics Derivatives
News headline image
Omeros (OMER) Q1 2026 Earnings Transcript ↗
Omeros (OMER) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Omeros Q1 Earnings Call Highlights ↗
Omeros (NASDAQ:OMER) reported first-quarter 2026 net income of $56.1 million, or $0.78 per share, as the company began commercial sales of YARTEMLEA, its recently approved treatment for hematopoietic... 
Via MarketBeat
Topics Earnings
News headline image
Omeros Corporation Reports First Quarter 2026 Financial Results
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026
From Omeros Corporation
Via Business Wire
News headline image
Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)
From Omeros Corporation
Via Business Wire
These stocks are gapping in today's session ↗
Via Chartmill
News headline image
Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026
From Omeros Corporation
Via Business Wire
News headline image
Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment
From Omeros Corporation
Via Business Wire
News headline image
Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program
From Omeros Corporation
Via Business Wire
News headline image
Omeros Announces First Commercial Sales of YARTEMLEA®
From Omeros Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.